<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chenodeoxycholic acid (chenodiol): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chenodeoxycholic acid (chenodiol): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Chenodeoxycholic acid (chenodiol): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="15547" href="/d/html/15547.html" rel="external">see "Chenodeoxycholic acid (chenodiol): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="91296" href="/d/html/91296.html" rel="external">see "Chenodeoxycholic acid (chenodiol): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F46233250"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Appropriate use</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Because of the potential hepatotoxicity of chenodiol, poor response rate in some subgroups of chenodiol treated patients, and an increased rate of a need of cholecystectomy in other chenodiol treated subgroups, chenodiol is not an appropriate treatment for many patients with gallstones. Chenodiol should be reserved for carefully selected patients and treatment must be accompanied by systematic monitoring for liver function alterations. Aspects of patient selection, response rates and risks versus benefits are given in the insert.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F10484405"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Chenodal</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F13806079"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Bile Acid</li></ul></div>
<div class="block doa drugH1Div" id="F10484462"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="529c36af-0b0f-4bf3-8231-8fde3d132024">Cerebrotendinous xanthomatosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebrotendinous xanthomatosis (off-label use):</b>
<b>Oral:</b> 250 mg 3 times daily for at least 1 year (Berginer 1984; Duell 2018).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c094826a-cdf0-4c2a-9f84-dad10fcb7c49">Gallstone dissolution</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallstone dissolution (monotherapy):</b>
<b>Oral:</b> Initial: 250 mg twice daily for 2 weeks, then increase dose by 250 mg/day each week until the recommended maintenance dose or maximum tolerated dose is achieved; maintenance: 13 to 16 mg/kg/day in 2 divided doses. <b>Note:</b> Dosages &lt;10 mg/kg are usually ineffective and may increase the risk of cholecystectomy. If diarrhea occurs, temporarily decrease dose; once symptoms resolve, attempt to reinstate the previous dose. Discontinue treatment if there is no response by 18 months; safe use beyond 24 months has not been established.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallstone dissolution (combination therapy; off-label dose):</b>
<b>Oral:</b> 5 to 7.5 mg/kg/day once daily at bedtime, in combination with ursodeoxycholic acid, with or without adjuvant lithotripsy (Jazrawi 1992; Pereira 1997; Petroni 2001).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990173"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling. </p></div>
<div class="block doha drugH1Div" id="F50987522"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Preexisting hepatic impairment:</i> There are no dosage adjustments provided in the manufacturer’s labeling; avoid use in patients with preexisting hepatic impairment. Contraindicated for use in presence of known hepatocyte dysfunction or bile duct abnormalities.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Aminotransferase level 1.5 to 3 times ULN persisting for &gt;3 to 6 months:</i> Temporarily withhold treatment; resume when aminotransferases levels return to normal.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Aminotransferase level &gt;3 times ULN:</i> Discontinue treatment immediately.</p></div>
<div class="block dot drugH1Div" id="F46233252"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Diarrhea:</i> Temporarily decrease dose; resume previous dose when diarrhea resolves. Discontinuation of therapy may be required for persistent diarrhea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Increased cholesterol:</i> Discontinue treatment if cholesterol increases above acceptable age-adjusted limit</p></div>
<div class="block dop drugH1Div" id="F52812572"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="91296" href="/d/html/91296.html" rel="external">see "Chenodeoxycholic acid (chenodiol): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="529c36af-0b0f-4bf3-8231-8fde3d132024">Cerebrotendinous xanthomatosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebrotendinous xanthomatosis:</b> Limited data available: Infants, Children, and Adolescents: Oral: Usual dose: 10 to 15 mg/kg/day divided 1 to 3 times daily; maximum daily dose: 750 mg/<b>day; </b>in infants and young children, a lower dose of 5 mg/kg/day in 3 divided doses has been suggested by some experts (Berginer 2009; European Medicines Agency [chenodeoxycholic acid 2017]; Huidekoper 2016; Kaufman 2012; Salen 2017; Setchell 2006; van Heijst 1998)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c094826a-cdf0-4c2a-9f84-dad10fcb7c49">Gallstone dissolution</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallstone dissolution:</b> Limited data available; not routinely used for cholelithiasis in pediatric patients; use has been replaced by other treatments (Salen 2017): Children ≥12 years and Adolescents: Oral: 15 mg/kg/day divided 3 times daily with meals; dosing based on reported experience in three obese pediatric patients (age range: 12 to 13 years); <b>Note:</b> Not first-line therapy due to frequent side effects (eg, increased LFT, diarrhea) and other therapeutic options available (Podda 1982)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21b8ff79-eea5-4337-84e6-e674575a09b3">Inborn errors of bile acid biosynthesis; steroid dehydrogenase or reductase deficiencies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inborn errors of bile acid biosynthesis; steroid </b>
<b>dehydrogenase or reductase deficiencies (susceptible)</b>
<b>:</b> Very limited data available: <b>Note:</b> Due to the rarity of the disease states, data is limited to small case series and case reports. Adjust dose based upon targeted bile acid or biosynthesis intermediate compound concentrations. Combination therapy with ursodeoxycholic acid (ursodiol) dependent on specific deficiency, and phenotypic presentation of syndrome. Infants, Children, and Adolescents: Oral: Usual initial range: 5 to 10 mg/kg/day divided once or twice daily; higher initial doses of 11 to 18 mg/kg/day have also been reported; a maintenance dose of 5 mg/kg/day was the most frequently reported and initiated once targeted bile acid normalized or stabilized (depending upon the syndrome) (Clayton 1996; Clayton 2011; Dai 2014; Ichimiya 1990; Riello 2010).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729630"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F52729631"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: Use extreme caution; contraindicated for use in presence of known hepatocyte dysfunction or bile duct abnormalities. A case report describes an infant who developed hepatoxicity during therapy (jaundice, hepatomegaly) at 15 mg/kg/day dose; chenodiol was discontinued until clinical parameters normalized, then restarted at a reduced dose (5 mg/kg/day) without recurrence of hepatotoxicity (Huidekoper 2016).</p></div>
<div class="block adr drugH1Div" id="F240019"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (dose-related; 30% to 40%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum transaminases (dose-related; transient: ≥30%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Hepatic: Increased serum aspartate aminotransferase (&gt;3 x ULN: 2% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum triglycerides (females), increased LDL cholesterol, increased serum cholesterol (total)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal cramps, abdominal pain, anorexia, biliary colic, bowel urgency, constipation, dyspepsia, epigastric discomfort, flatulence, heartburn, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased white blood cell count</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hepatic: Chronic active hepatitis</p></div>
<div class="block coi drugH1Div" id="F240030"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hepatocyte dysfunction or bile ductal abnormalities (eg, intrahepatic cholestasis, primary biliary cirrhosis, sclerosing cholangitis); gallbladder confirmed as nonvisualizing after two consecutive single doses of dye; radiopaque stones; gallstone complications or compelling reasons for gallbladder surgery (eg, unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, biliary gastrointestinal fistula); use in pregnancy or in patients who can become pregnant.</p></div>
<div class="block war drugH1Div" id="F240017"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diarrhea: Dose-related diarrhea commonly occurs (up to 40% of patients); may occur at any time, but is most common during treatment initiation. Diarrhea is usually mild and does not interfere with therapy; however, diarrhea may be severe and a temporary dosage reduction or discontinuation may be required. Antidiarrheal agents may be of benefit in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Drug-induced liver toxicity may occur (dose-related); close monitoring of serum aminotransferase levels recommended during therapy. Aminotransferase elevations &gt;3 times ULN have been reported; prompt discontinuation of therapy recommended. Transaminase levels usually return to normal after chenodiol is withheld. Temporarily withhold therapy for transient transaminase elevations of 1.5 to 3 times ULN. Biochemical and histologic chronic active hepatitis has been reported (rare case reports), although a causal relationship to chenodiol could not be determined.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Colon cancer: Epidemiologic studies have suggested that bile acids may increase the risk of colon cancer. Evidence is weak and conflicting; however, a potential link between bile acids and colon cancer cannot be ruled out.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Avoid use in patients with preexisting hepatic impairment or elevated liver enzymes; use contraindicated in patients with known hepatocyte dysfunction or bile ductal abnormalities.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <b> [US Boxed Warning]: Due to the hepatotoxicity potential, poor response rate in certain subgroups, and an increased rate of cholecystectomy necessary in other subgroups, chenodiol is not an appropriate treatment for many patients with gallstones. Use should be reserved to carefully selected patients; treatment must be accompanied with liver function monitoring.</b> Studies have shown dissolution rates are higher in patients with small (&lt;15 mm in diameter), radiolucent, and/or floatable stones. Radiopaque (calcified or partially calcified) stones and bile pigment stones do not respond to bile acid dissolution therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of therapy: Response to therapy should be monitored with oral cholecystograms or ultrasonograms at 6- to 9-month intervals. Complete dissolution should then be confirmed by a repeat test 1 to 3 months after continued therapy. If partial dissolution is not observed by 9 to 12 months, complete dissolution is unlikely. If no response is observed by 18 months, therapy should be discontinued; safety beyond 24 months of use has not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallstone recurrence: May occur within 5 years in approximately 50% of patients; serial cholecystograms or ultrasonograms are recommended to monitor for recurrence. Prophylactic doses have not been established and reduced doses cannot be recommended. Long-term consequences of repeated courses or chenodiol are not known.</p></div>
<div class="block foc drugH1Div" id="F240027"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chenodal: 250 mg</p></div>
<div class="block geq drugH1Div" id="F240012"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16321898"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Chenodal Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $601.66</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F22460185"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Prescriptions are only dispensed by Dohmen Life Science Services Chenodal Total Care Program which may be contacted at 866-758-7068.</p></div>
<div class="block admp drugH1Div" id="F52614057"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be taken without regard to meals.</p></div>
<div class="block use drugH1Div" id="F240028"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gallstone dissolution:</b> Dissolution of radiolucent cholesterol gallstones in select patients as an alternative to surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Will not dissolve calcified (radiopaque) or radiolucent bile pigment stones.</p></div>
<div class="block off-label drugH1Div" id="F25722052"><span class="drugH1">Use: Off-Label: Adult</span><p>Cerebrotendinous xanthomatosis</p></div>
<div class="block mst drugH1Div" id="F56411493"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299012"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F240021"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aluminum Hydroxide: May decrease the serum concentration of Chenodiol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the serum concentration of Chenodiol. Management: Administration of chenodiol 5 hours or more after bile acid sequestrants may reduce the magnitude of this interaction.  Monitor for decreased therapeutic effects of chenodiol in patients receiving bile acid sequestrants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the therapeutic effect of Chenodiol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Chenodiol may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53539389"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in women who may become pregnant.</p></div>
<div class="block pri drugH1Div" id="F10484407"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in women who are pregnant. Adverse events were observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F20613509"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if chenodiol is excreted in breast milk. The manufacturer recommends that caution be exercised when administering chenodiol to breastfeeding women.</p></div>
<div class="block mop drugH1Div" id="F240025"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum aminotransferase levels (monthly for first 3 months, then every 3 months thereafter during therapy); serum cholesterol (every 6 months); oral cholecystograms and/or ultrasonograms (at 6- to 9-month intervals for response to therapy); dissolutions of stones should be confirmed 1 to 3 months later</p></div>
<div class="block pha drugH1Div" id="F240015"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Chenodiol (chenodeoxycholic acid) is a naturally occurring human bile acid, normally constituting one-third of the total bile acid pool. In patients with cholesterol gallstones, chenodiol is believed to suppress hepatic synthesis of cholesterol and cholic acid, and inhibit biliary cholesterol secretion, which leads to increased production of cholesterol unsaturated bile thereby allowing for dissolution of gallstones. </p></div>
<div class="block phk drugH1Div" id="F10484414"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid, almost completely absorbed in proximal small intestine (Crosignani 1996) </p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~1600 L (Crosignani 1996) </p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Converted hepatically to taurine and glycine conjugates and secreted in bile; extensive first-pass hepatic clearance; undergoes enterohepatic circulation; further metabolized in colon by bacteria to lithocholic acid; small portion of lithocholate is absorbed and converted to sulfolithocholyl conjugates in the liver</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life: ~45 hours (Crosignani 1996) </p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~80%, as lithocholate) </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539772"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Chenodeoxycholic a</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Chenisolve</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Chendol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Chenodal</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11464194">
<a name="11464194"></a>Bel, S, Garcia-Patos V, Rodriquez L, et al, “Cerebrotendinous Xanthomatosis,” <i>J Am Acad Dermatol</i>, 2001, 45(2):292-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/11464194/pubmed" id="11464194" target="_blank">11464194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19117873">
<a name="19117873"></a>Berginer VM, Gross B, Morad K, et al. Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. <i>Pediatrics</i>. 2009;123(1):143-147.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/19117873/pubmed" id="19117873" target="_blank">19117873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6504105">
<a name="6504105"></a>Berginer VM, Salen G, and Shefer S, “Long-Term Treatment of Cerebrotendinous Xanthomatosis With Chenodeoxycholic Acid,” <i>N Engl J Med</i>, 1984, 311(26):1649-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/6504105/pubmed" id="6504105" target="_blank">6504105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20414172">
<a name="20414172"></a>Bonnot O, Fraidakis MJ, Lucanto R, et al, “Cerebrotendinous Xanthomatosis Presenting With Severe externalized disorder: Improvement After One Year of Treatment With Chenodeoxycholic Acid,” <i>CNS Spectr</i>, 2010, 15(4):231-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/20414172/pubmed" id="20414172" target="_blank">20414172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chenodal.1">
<a name="Chenodal.1"></a>Chenodal (chenodiol) [prescribing information]. San Diego, CA: Travere Therapeutics; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21229319">
<a name="21229319"></a>Clayton PT. Disorders of bile acid synthesis. <i>J Inherit Metab Dis</i>. 2011;34 593-604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/21229319/pubmed" id="21229319" target="_blank">21229319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8707100">
<a name="8707100"></a>Clayton PT, Mills KA, Johnson AW, et al. Delta 4-3-oxosteroid 5ß-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. <i>Gut</i>. 1996;38:623-628.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/8707100/pubmed" id="8707100" target="_blank">8707100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8743334">
<a name="8743334"></a>Crosignani A, Setchell KDR, Invernizzi P, et al. Clinical pharmacokinetics of therapeutic bile acids. <i>Clin Pharmacokinetic</i>. 1996;30(5):333-358.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/8743334/pubmed" id="8743334" target="_blank">8743334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24658845">
<a name="24658845"></a>Dai D, Mills PB, Footitt E, et al. Liver disease in infancy caused by oxysterol 7 α-hydroxylase deficiency: successful treatment with chenodeoxycholic acid. <i>J Inherit Metab Dis</i>. 2014;37(5):851-861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/24658845/pubmed" id="24658845" target="_blank">24658845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30017468">
<a name="30017468"></a>Duell PB, Salen G, Eichler FS, et al. Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. <i>J Clin Lipidol</i>. 2018;12(5):1169-1178. doi:10.1016/j.jacl.2018.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/30017468/pubmed" id="30017468" target="_blank">30017468</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  European Medicines Agency. Chenodeoxycholic acid [summary of product characteristics]. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004061/WC500226784.pdf. Updated June 29, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20301583">
<a name="20301583"></a>Federico A, Dotti MT, and Gallus GN, (Updated January 25, 2008). “Cerebrotendinous Xanthomatosis.” In: <i>GeneReviews</i> at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2010. Available at http://www.genetests.org. Accessed August 2, 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/20301583/pubmed" id="20301583" target="_blank">20301583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26156051">
<a name="26156051"></a>Huidekoper HH, Vaz FM, Verrips A, Bosch AM. Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment. <i>Eur J Pediatr</i>. 2016;175(1):143-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/26156051/pubmed" id="26156051" target="_blank">26156051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2248502">
<a name="2248502"></a>Ichimiya H, Nazer H, Gunasekaran T, et al. Treatment of chronic liver disease caused by 3ß-hydroxy-∆5-C27-steroid dehydrogenase deficiency with chenodeoxycholic acid. <i>Archives of Disease in Childhood</i>. 1990;65:1121-1124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/2248502/pubmed" id="2248502" target="_blank">2248502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1568660">
<a name="1568660"></a>Jazrawi RP, Pigozzi MG, Galatola G, et al, “Optimum Bile Acid Treatment for Rapid Gall Stone Dissolution,” <i>Gut</i>, 1992, 33(3):381-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/1568660/pubmed" id="1568660" target="_blank">1568660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22197981">
<a name="22197981"></a>Kaufman MA, Gonzalez-Moron D, Consalvo D, et al. Cerebrotendinous xanthomatosis revealed in drug-resistant epilepsy diagnostic workup. <i>Am J Med Sci</i>. 2012;343(4):332-333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/22197981/pubmed" id="22197981" target="_blank">22197981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12187304">
<a name="12187304"></a>Maeda K, Kimura A, Yamoto Y, et al. Oral bile acid treatment in two Japanese patients with Zellweger syndrome. <i>Journal of Pediatric Gastroenterology and Nutrition</i>. 2002;35:227-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/12187304/pubmed" id="12187304" target="_blank">12187304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9286247">
<a name="9286247"></a>Pereira SP, Veysey MJ, Kennedy C, et al. Gallstone dissolution with oral bile acid therapy. Importance of pretreatment CT scanning and reasons for nonresponse. <i>Dig Dis Sci</i>. 1997;42(8):1775-1782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/9286247/pubmed" id="9286247" target="_blank">9286247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11136285">
<a name="11136285"></a>Petroni ML, Jazrawi RP, Pazzi P, et al, “Ursodeoxycholic Acid Alone or With Chenodeoxycholic Acid for Cholesterol Gallstones: A Randomized Multicentre Trial. The British-Italian Gallstone Study Group,” <i>Aliment Pharmacol Ther</i>, 2001, 15(1):123-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/11136285/pubmed" id="11136285" target="_blank">11136285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7181529">
<a name="7181529"></a>Podda M, Zuin M, Dioguardi ML, et al. Successful treatment of gallstones with bile acids in obese adolescents. <i>Arch Dis Child</i>. 1982;57(12):956-958.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/7181529/pubmed" id="7181529" target="_blank">7181529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20400917">
<a name="20400917"></a>Riello L, Antiga LD, Guido M, et al. Titration of bile acid supplements in 3ß-hydroxy-∆5-C27-steroid dehydrogenase/isomerase deficiency. <i>JPGN</i>. 2010;50:655-660.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/20400917/pubmed" id="20400917" target="_blank">20400917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28980151">
<a name="28980151"></a>Salen G, Steiner RD. Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX). <i>J Inherit Metab Dis</i>. 2017;40(6):771-781.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/28980151/pubmed" id="28980151" target="_blank">28980151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16819396">
<a name="16819396"></a>Setchell KDR, Heubi JE. Defects in bile acid biosynthesis – diagnosis and treatment. <i>Journal of Pediatric Gastroenterology and Nutrition</i>. 2006;43:17-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/16819396/pubmed" id="16819396" target="_blank">16819396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9578968">
<a name="9578968"></a>Van Heijst AJ, Verrips A, Wevers RA, et al. Treatment and follow-up of children with cerebrotendinous xanthomatosis. <i>Eur J Pediatr</i>. 1998;157(4):313-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chenodeoxycholic-acid-chenodiol-drug-information/abstract-text/9578968/pubmed" id="9578968" target="_blank">9578968</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15546 Version 139.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
